[go: up one dir, main page]

UY29370A1 - Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones - Google Patents

Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones

Info

Publication number
UY29370A1
UY29370A1 UY29370A UY29370A UY29370A1 UY 29370 A1 UY29370 A1 UY 29370A1 UY 29370 A UY29370 A UY 29370A UY 29370 A UY29370 A UY 29370A UY 29370 A1 UY29370 A1 UY 29370A1
Authority
UY
Uruguay
Prior art keywords
tiazol
derivatives
compositions
contain
applications
Prior art date
Application number
UY29370A
Other languages
English (en)
Inventor
Sarah King
Andrew Baxter
Austen Pimm
Chris Luckhurst
Mark Furber
James Reuberson
Ian Millichip
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY29370A1 publication Critical patent/UY29370A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona compuestos de fórmula (I), o una sal farmacéuticamente aceptable de los mismos, en donde A, R1, R2, y R3, son como se define en la memoria descriptiva; un proceso para su preparación; composiciones farmacéuticas que los contienen; y su uso en terapia.
UY29370A 2005-02-11 2006-02-10 Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones UY29370A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0500336 2005-02-11

Publications (1)

Publication Number Publication Date
UY29370A1 true UY29370A1 (es) 2006-10-02

Family

ID=36793310

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29370A UY29370A1 (es) 2005-02-11 2006-02-10 Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones

Country Status (4)

Country Link
AR (1) AR052900A1 (es)
TW (1) TW200639156A (es)
UY (1) UY29370A1 (es)
WO (1) WO2006085815A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9981959B2 (en) * 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
RS62164B1 (sr) 2015-02-16 2021-08-31 Univ Queensland Sulfoniluree i srodna jedinjenja i njihova upotreba
CA3059458A1 (en) 2017-05-24 2018-11-29 The University Of Queensland Novel compounds and uses
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
KR102669722B1 (ko) 2017-07-07 2024-05-29 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
RU2020110366A (ru) * 2017-08-15 2021-09-16 Инфлазоум Лимитед Новые соединения сульфонамидкарбоксамидов
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
UY37847A (es) * 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
MX2020001778A (es) 2017-08-15 2020-03-24 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida.
PE20210050A1 (es) 2017-11-09 2021-01-08 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
EP3707137A1 (en) 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
JP2022505525A (ja) * 2018-10-24 2022-01-14 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
SG10201909596RA (en) * 2019-10-14 2021-05-28 Esco Aster Pte Ltd Synthesis of Tyrosine Kinase Inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1735497A (en) * 1996-02-26 1997-09-10 Sumitomo Pharmaceuticals Company, Limited Sulfonylureidopyrazole derivatives
WO2003039451A2 (en) * 2001-11-08 2003-05-15 Fujisawa Pharmaceutical Co., Ltd. Thiazole pyridazinones as adenosine antagonists
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul

Also Published As

Publication number Publication date
TW200639156A (en) 2006-11-16
WO2006085815A1 (en) 2006-08-17
AR052900A1 (es) 2007-04-11

Similar Documents

Publication Publication Date Title
UY29370A1 (es) Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
UY30976A1 (es) Nuevos derivados de quinolina, composiciones farmaccuticas que los contienen, procesos de preparacion y aplicaciones.
GT200600518A (es) Derivados de pirimidina
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
UY28342A1 (es) Nuevos compuestos
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
UY29875A1 (es) Compuestos quimicos
UY30759A1 (es) Compuestos quimicos
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
CR11857A (es) Compuestos pirazolicos 436
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
UY28572A1 (es) Compuestos novedosos
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
UY31069A1 (es) Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones
SV2009003281A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.0
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
UY30327A1 (es) Nuevos compuestos ii
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
UY29732A1 (es) Derivados de benzotiazolonas, procesos de preparación, composiciones y combinaciones que los contienen y aplicaciones
UY29234A1 (es) Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones.
UY31456A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
UY30736A1 (es) Compuestos quimicos 537

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160808